ArticleNature microbiology2024
OPENPichia: licence-free Komagataella phaffii chassis strains and toolkit for protein expression.
Article in Nature microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Cloning and Protein Expression of CpEst in Komagataella phaffii.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Yarrowia lipolytica and Komagataella phaffii (Pichia pastoris) as Hosts for Heterologous Expression of Lipases.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Yeast species resource exploration and application in cell factories.Synthetic and systems biotechnology · 2026Review
- Metabolic engineering ofApplied and environmental microbiology · 2026Review
- Host-Informed Engineering of Glycosylation in Komagataella phaffii for Human Biantennary N-Linked Glycans.Research square · 2026Article
- One Yeast, Sixteen Synthetic Chromosomes, Infinite Possibilities.Yeast (Chichester, England) · 2026Review
- FormatotrophicSynthetic and systems biotechnology · 2026Article
- Development and Application of a Cumate-Inducible Promoter, PMicrobial biotechnology · 2026Article
- Progress in the Expression, Purification, and Characterization of Recombinant Collagen.Bioengineering (Basel, Switzerland) · 2026Review
- Yeast-Based Vaccine Platforms: Applications and Key Insights from the COVID-19 Era.Biomolecules · 2026Review
- Engineering yeast for sustainable bioproduction of tryptophan-derived aromatic compounds.FEMS yeast research · 2026Review
- Pichia pastoris Genomic Resources: Accessibility, Recommendations, and Pitfalls.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Decoding the Genome of the Komagataella phaffii Type Strain CBS 2612.Yeast (Chichester, England) · 2025Article
- The MFα signal sequence in yeast-based protein secretion: challenges and innovations'.Applied microbiology and biotechnology · 2025Review
- Advances in CRISPR-enabled genome-wide screens in yeast.FEMS yeast research · 2025Review
- Characterization of the exopolysaccharides produced by the industrial yeast Komagataella phaffii.Journal of industrial microbiology & biotechnology · 2024Article
- Effect of cell retention techniques in Komagataella phaffii lab-scale continuous processes.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The industrial yeast Komagataella phaffii (formerly named Pichia pastoris) is commonly used to synthesize recombinant proteins, many of which are used as human therapeutics or in food. However, the basic strain, named NRRL Y-11430, from which all commercial hosts are derived, is not available without restrictions on its use. Comparative genome sequencing leaves little doubt that NRRL Y-11430 is derived from a K. phaffii type strain deposited in the UC Davis Phaff Yeast Strain Collection in 1954. We analysed four equivalent type strains in several culture collections and identified the NCYC 2543 strain, from which we started to develop an open-access Pichia chassis strain that anyone can use to produce recombinant proteins to industry standards. NRRL Y-11430 is readily transformable, which we found to be due to a HOC1 open-reading-frame truncation that alters cell-wall mannan. We introduced the HOC1 open-reading-frame truncation into NCYC 2543, which increased the transformability and improved secretion of some but not all of our tested proteins. We provide our genome-sequenced type strain, the hoc1
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.